Genelabs Technologies Inc. said the European patent office approved its patent application covering T-cell leukemia virus peptide technology, which is used in the company's diagnostic Human T-Cell Lymphotropic Virus blood-screening tests.
HTLV-I and HTLV-II cause immune disorders and certain cancers.
The technology has also been patented in the U.S. and Australia.
Both tests are sold world-wide.
In Nasdaq Stock Market trading, Genelabs stock closed, unchanged, at $3.125.
